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Circulating tumor cells (CTCs). What exactly are these cells that
we liken to “finding a needle in a haystack?” CTCs originate
from a primary tumor, are often but not always of epithelial phe-
notype, and are dispersed in the peripheral circulation among
millions of (somewhat smaller) leukocytes per milliliter and bil-
lions of red blood cells. They can and do interact with the
proteins and formed elements of blood. They are the subject
of rapidly increasing interest in research and clinical diagnos-
tics. But are they the same cells that initiate metastases? Recent
improvements to animal models of bloodborne metastasis have
begun to elucidate the physical determinants of tissue tropism
in metastasis. One thing for certain is that CTC count is now
recognized as a strong predictor of patient survival in many can-
cers, such as those originating from breast and prostate. This
Special Topic of Frontiers of Oncology attempts to address some
of the important questions surrounding CTCs: what are these
cells, how may we study and target them therapeutically, and
what secrets they may hold in controlling and combating cancer
metastasis.
Eleven of the 15 papers in this Special Topic come from
investigators of the collaborative network of Physical Science-
Oncology Centers established in 2009 by the US National
Cancer Institute. These 12 centers across the United States bring
together biologists, clinicians, physical scientists, and engineers
to develop innovative new ways to understand and fight can-
cer. The specific centers represented here include: the Cornell
University Center on the Microenvironment and Metastasis; the
Center for Transport Oncophysics of the Methodist Hospital
Research Institute; the Moffitt Cancer Center Physical Science-
Oncology Center; the 4DB Center of Scripps Research Institute;
and the Dana-Farber Cancer Institute Physical Science-Oncology
Center.
The papers in this Special Topic can be categorized into one
of three parts. In the first part, therapies directed toward CTCs in
the bloodstream, and the responses of CTCs to cancer therapies,
are considered. This subject is broadly reviewed by Greene et al.
(2012) and then reviewed in the context of cancer stem cells by
Faltas (2012). Li and King (2012) discuss cell adhesion receptors
and how they can be targeted to neutralize CTCs. Liesveld (2012)
discusses the targeting of myelogenous leukemia stem cells in
the bloodstream, and Paolo Decuzzi and coworkers present data
on the adhesion response of a model CTC cell line to curcumin
treatment (Palange et al., 2012).
The second group of papers focuses on the basic science of
CTCs, and how we might expect them to behave while in the cir-
culation. Geng et al. (2012) show that the breast cancer biomarker
MUC1 can act as a simultaneous adhesion counter-receptor for
both endothelial E-selectin and ICAM-1, and they present a new
model for the metastatic adhesion cascade paradigm. Burdick
et al. (2012) consider not only the adhesion characteristics of
CTCs to E-selectin, but propose that surface ligand expression
may signal phenotypic changes of cancer stem cells. Rejniak
(2012) presents a computational model that can be used to
simulate the shear-induced deformation of CTCs in the blood-
stream. In a pair of related papers, Tormoen et al. (2012b)
pose the question of whether CTCs play a role in coagulation
and thrombosis in the bloodstream, and then Lee et al. (2012)
describe their theoretical model of procoagulant CTCs under
flow.
The third and final part of this special issue is focused on the
characterization of patient CTCs, including new methods ded-
icated to this goal. Another contribution from Tormoen et al.
(2012a) presents new coagulation factor probes for the identifica-
tion of procoagulant CTCs. Diamond et al. (2012) describe their
characterization of prostate cancer CTCs isolated from patient
blood. Garcia-Villa et al. (2012) measured the γ-H2AX levels in
CTCs obtained from patients undergoing chemotherapy. Finally,
a pair of papers fromMcCarty and coworkers describes the appli-
cation of precise image analysis methods to measure the density
and volume of patient CTCs in ovarian (Phillips et al., 2012b) and
breast cancer (Phillips et al., 2012a), including a comparison with
properties measured for normal blood cells.
The images featured on page 2 of this E-book, provided by
Andrew Hughes of Cornell University, show viable CTCs isolated
from a pancreatic cancer patient (upper image). The epithe-
lial cancer cells stain positive for cytokeratin (red), and negative
for the leukocyte marker CD45 (green), and show characteris-
tically large nuclei stained in blue. The lower scanning electron
micrograph shows a human leukocyte resting on a layer of hal-
loysite nanotubes; these cells are unable to spread onto halloysite
which enables efficient isolation of patient CTCs. This research is
described in the lead paper by Greene et al. (2012).
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